EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions

Paola Rogliani iD, Petros Bakakos iD, Daiana Stolz iD, Alessio Piraino iD, Laura Franzini, Elena Nudo, Luca Di Palma iD, Guy Brusselle iD

International Journal of Chronic Obstructive Pulmonary Disease · 2026

DOI: 10.2147/copd.s603262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Paola Rogliani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Cardiovascular Diseases, Beclomethasone, Glycopyrrolate. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluated the real-world effectiveness and safety of extrafine single-inhaler triple therapy (SITT) with beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in chronic obstructive pulmonary disease (COPD) patients with diverse comorbidity burdens, cardiovascular (CV) history, or CV risk. Patients and Methods: A pooled analysis of six observational studies assessed outcomes in subgroups with 1-2 or ≥3 comorbidities, CV history, or CV risk. Endpoints included COPD Assessment Test (CAT) scores, exacerbation, lung function (FEV1), adherence (TAI-10), and cardiopulmonary events, evaluated at 3, 6, and 12 months. Comparisons were made with reference populations (0 comorbidities, no CV history, and no CV risk).

Results

Among 5356 patients, 2431 had 1-2 comorbidities, 1087 had ≥3, 312 had a CV history, and 117 met CV-risk criteria. CAT scores decreased significantly in all subgroups following SITT initiation. Patients with comorbidities showed smaller CAT improvements vs those without, while CV history/risk groups showed greater CAT improvements than their reference groups up to month 6. Regardless of comorbidity burden or CV history, most patients remained exacerbation-free and FEV1 improved, with no long-term differences between groups. Adherence improved as well, with patients with ≥3 comorbidities potentially showing higher adherence over the long term. Cardiopulmonary events were more frequent in higher-comorbidity groups early on but became similar over time. Patients with a CV history consistently reported more cardiopulmonary events than those without, while those with CV risk achieved similar results compared to no-risk group at any time point.

Conclusion

This analysis provides real-world evidence supporting extrafine BDP/FF/GB SITT as an effective and safe option for COPD patients with comorbidities, including CV history or risk. These findings help address an evidence gap in vulnerable populations and support timely initiation of SITT in high-risk patients in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveCardiovascular DiseasesBeclomethasoneGlycopyrrolateBronchodilator AgentsLungFormoterol FumarateAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsGlucocorticoidsHumansTreatment OutcomeFemaleComorbidityDrug CombinationsAgedAdministration, InhalationMaleTime FactorsMiddle AgedRecovery of FunctionForced Expiratory VolumeMedication AdherenceHeart Disease Risk FactorsRisk FactorsNebulizers and VaporizersDisease Progression

Stichwörter der Autor:innen

beclometasone dipropionatecardiovascular eventscardiovascular riskcomorbidity burdenformoterol fumarateglycopyrronium bromide

Substanzen

Drug CombinationsBeclomethasoneGlycopyrrolateBronchodilator AgentsFormoterol FumarateAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsGlucocorticoids

Autor:innen und Institutionen

  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome, Rome, Italy.
  • 1st University Department of Respiratory Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Clinic of Respiratory Medicine and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Global Medical Affairs, Chiesi Farmaceutici S.p.A., Parma, Italy.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Paola Rogliani, Petros Bakakos, Daiana Stolz, Alessio Piraino, Luca Di Palma, Guy Brusselle

Zitieren

APA

Rogliani, P., Bakakos, P., Stolz, D., Piraino, A., Franzini, L., Nudo, E., Di Palma, L., & Brusselle, G. (2026). Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s603262

Vancouver

Rogliani P, Bakakos P, Stolz D, Piraino A, Franzini L, Nudo E, et al. Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s603262

BibTeX
@article{Rogliani2026,
  author = {Rogliani, Paola and Bakakos, Petros and Stolz, Daiana and Piraino, Alessio and Franzini, Laura and Nudo, Elena and Di Palma, Luca and Brusselle, Guy},
  title = {Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2026},
  doi = {10.2147/copd.s603262}
}
Kostenlos starten →